DR. BRYAN LAWLIS JOINS GLYCOFI BOARD OF DIRECTORS

Lebanon, NH and Cambridge, MA (March 16, 2005) – GlycoFi, Inc., a privately-held biotechnology company, is pleased to announce today that it has appointed V. Bryan Lawlis, Ph.D., President and CEO of Aradigm Corporation to its Board of Directors. Dr. Lawlis, a 25-year biotech industry veteran, brings his broad experience in therapeutic protein development and manufacturing, to strengthen GlycoFi's Board as its first outside Director.

At Aradgim, Dr. Lawlis has served as President and Chief Executive Officer since August 2004, as President and Operating Officer from June 2003 to August 2004 and as Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman 1999 to 2001, when it was sold to Diosynth, a division of Akzo Nobel. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences.

"Bryan's background will strengthen GlycoFi's strategic capabilities in the area of product development and will assist us in developing deep relationships with our biotech and biopharma collaborators" said Sylvie Gregoire, CEO of GlycoFi, Inc.

"We are honored to make this appointment and I look forward to working with Bryan to build GlycoFi into a leading biotech company," added Charles Hutchinson, Co-Founder of GlycoFi and Chairman of GlycoFi's Board of Directors.

Dr. Lawlis holds a Ph.D. in Biochemistry from Washington State University and a B.A. in Microbiology from the University of Texas at Austin.

Commented Dr. Lawlis: "As the pharmaceutical and biotechnology industries are exploring ways to develop improved products by controlling glycosylation of proteins, GlycoFi is positioned as a leader in developing technology to meet this need. I am both impressed and excited about the potential for this approach and look forward to assisting the company with their strategic initiatives."

About GlycoFi

GlycoFi, Inc. is a biotechnology company that leverages its pioneering protein production technology to develop, produce and commercialize Next Generation BiotherapeuticsT, alone and in partnership with other leading biopharmaceutical companies. Sugars, or glycosylation, on the surface of a protein are known to influence critical pharmaceutical properties of therapeutic proteins and monoclonal antibodies. GlycoFi is the leader in the in the area of glycosylation engineering in living systems, and its patented, scaleable technology uniquely allows its partners to create specific human glycosylation variants of any therapeutic glycoprotein. For the first time, GlycoFi and its partners can systematically research the impact of a protein's glycovariants on its pharmaceutical properties, enabling the optimization of biological activity, receptor binding, serum half-life, and potency of the drug candidate, thereby reducing the overall development risk of the project. GlycoFi has several products in research and pre-clinical development and is working on other products in collaboration with leading biopharmaceutical companies. For more information, please visit www.glycofi.com.

GlycoFi Contacts:

Michael Horvath
Chief Financial Officer, GlycoFi
mhorvath@glycofi.com
(603) 643-8186 x5106

Joan Kureczka
Kureczka/Martin Associates
jkureczka@aol.com
415.821.2413